Hamsters were immunized with either an affinitypurified preparation of equid herpesvirus 1 (EHV-1) glycoprotein 13 (gp 13) or synthetic peptides representing three sequences within the homologous glycoprotein of EHV-4, resulting in the production of antipeptide (in the case of peptide-immunized animals) or antivirus antibodies. The sera from gpl3-immunized hamsters contained antibodies which showed virusneutralizing activity and complement-mediated antibody lysis of EHV-l-infected target cells. These hamsters were protected from EHV-1 challenge. The characteristics of a panel of anti-gpl3 monoclonal antibodies (P28, P17, 14H7, 16E4 and 16H9) were assessed both in vivo and in vitro. 16E4 and P28 showed high levels of complement-mediated neutralization of virus, complement-mediated lysis of virusinfected target cells and passive protection of hamsters. Furthermore, epitope mapping studies demonstrated that this glycoprotein contains a neutralizing epitope recognized by EHV-1-immune horse serum. The data imply that gp 13 has potential as a candidate antigen for a molecular vaccine.
Introduction
Infection of the Syrian hamster with equid herpesvirus 1 (EHV-1) was demonstrated in 1942 (Anderson & Goodpasture, 1942) , virus replication occurring mainly in the liver which was pale in colour and contained Feulgen-positive inclusion bodies (Bracken & Randall, 1957) . The hamster has since been developed as a small animal model in which both humoral and cell-mediated immune responses to the virus have been investigated (Wilks & Coggins, 1977; Stokes et al., 1989) , protection from infection being observed following immunization with a glycoprotein-containing fraction of the viral envelope (Papp-Vid & Derbyshire, 1978) . This small animal model was used in the work described here to investigate the potential of glycoprotein 13 (gpl3) of EHV-1 as a vaccine candidate.
The effective design of a vaccine against EHV-1 infection of the horse is hindered by the existence of a serologically distinct virus type, EHV-4; these viruses are differentiated by the electrophoretic mobility of their DNA restriction fragments (Sabine et al., 1981 ; Studdert et al., 1981) , pattern of cross-neutralization (Burrows & Goodridge, 1973) and monoclonal antibody reactivity (Yeargen et al., 1985) .
EHV-1 isolates are responsible for abortion (Burrows et al., 1984) , respiratory disease (Burrows & Goodridge, 1979) , perinatal foal disease (Crandell & Angulo, 1985) and myeloencephalitis (Chowdhury et al., 1986) , whereas EHV-4 isolates are mainly responsible for respiratory disease (Mumford & Bates, 1984) . The increased frequency in EHV-l-associated paresis in the United Kingdom (Anonymous, 1989) has emphasized the need for a more suitable vaccine although the potential efficacy of vaccination is hindered by the ability of the virus to reactivate, demonstrated following the administration of corticosteroids (Edington et al., 1985; Browning et al., 1989) .
The glycoproteins of herpesviruses, which are expressed on the cell surface during virus replication (Jennings et al., 1987) , thus making them accessible targets for the immune system , have been examined for their potential as immunogens. EHV-1 infection results in the production of serum antibodies reactive against four type-common and two type-specific glycoproteins of the virus (Allen & Bryans, 1986) . Furthermore, the genes encoding the high abundance glycoproteins have been mapped (Allen & Yeargen, 1987) and at least three of these are genetically collinear with herpes simplex virus (HSV) glycoproteins B, C and E [gpB (gpl4), gpC (gpl3) and gpE] (Allen & Coogle, 1988) . Both the gp14 (Riggio et al., 1989; Whalley et al., 1989; W. A. Bonass et al., unpublished results) and the gpl3 (Allen & Coogle, 1988; L. Nicolson & D. E. Onions, 1990 ) genes of EHV-1 and EHV-4 have been cloned and sequenced.
Gpl3 (gp88) (Meredith et al., 1989) was selected for study because it shows considerable DNA and protein sequence identity with HSV-1 gpC, the receptor for the activated complement component C3b (Friedman et al., 1984) which enables the virus to evade complementmediated neutralization (McNearney et al., 1987) . Furthermore, the passive transfer of MAbs to gpC protects mice from infection (Rector et al., 1982; Kumel et al., 1985) and, recently, a vaccinia virus recombinant expressing the gpC gene of HSV-1 induced both a neutralizing antibody and a cell-mediated immune response, and protected animals from lethal HSV-1 challenge (Weir et al., 1989) . In the analogous EHV-1 situation, a vaccinia virus recombinant expressing the gpl 3 gene of EHV-1 induced neutralizing antibodies in guinea-pigs and protected hamsters from a lethal challenge (Guo et al., 1989) . The passive transfer of an MAb to gp 13 also provided a high degree of protection in the Syrian hamster (Stokes et al., 1989) .
In the studies described here, immunoaffinity-purified gpl3 from EHV-1 was prepared and evaluated as a vaccine candidate, murine MAbs against EHV-1 gpl3 were tested for their virus-neutralizing activity, ability to lyse target cells expressing EHV-1 antigens in vitro and protective efficacy, and peptides were synthesized using the primary sequence data of EHV-4 gpl 3 and evaluated in vivo.
Methods
Experimental animals. Female golden Syrian hamsters (Mesocricetus auratus) (6 to 8 weeks old) of the DSN inbred strain were used; these were obtained from Consort. Hamsters were bled by cardiac puncture following ether anaesthesia; approximately 1 ml of blood was removed on each occasion.
Virus. The strains of virus used in this study included the prototype EHV-1 strain Kentucky D (KyD) (Doll & Wallace, 1954) which had been passaged 300 times through hamsters and in tissue culture thereafter (Burrows, 1968) , and strain Abl, a low passage isolate from a case of abortion at Wood Ditton Stud. The 1942 EHV-4 isolate (Cullinane et al., 1988) was also used. Virus was purified by potassium tartrate gradient centrifugation (Lopez & O'Reilly, 1977) . Hamsters were challenged intraperitoneally with 2 × 10 s'3 TCID50 units (200 [.tl) of EHV-1 strain KyD.
Purifieationofgpl3. RK-13 cells (1-5 x 109) were infected with EHV -1 strain Abl (0.1 p.f.u./cell) and at 36 to 48 h post-infection (p.i.) the virus-containing supernatant was separated from cellular debris by centrifugation. The supernatant was then centrifuged at 12000 r.p.m. for 90 min. The pellet was solubilized in 0.5~ Triton X-100 at 0 °C for 1 h and then centrifuged at 100000 g for l h. The supernatant was loaded onto an affinity column which consisted of an anti-gpl3 MAb (92b) conjugated to Affi-Gel Hz (Bio-Rad) in a 2 ml column volume. The protein was eluted in 0.2 M-glycine-HC1 pH 2.2/0.1% Triton X-100, neutralized with an equal volume of 0.2 M-Tris and stored at -20 °C until use. The Mr of the molecule was assessed by Western blot analysis using MAb 92b.
Peptide synthesis. Peptides were synthesized using EHV-4 gpl3 sequence data. Three peptides were selected after predicting their immunogenicity on the basis of criteria which included hydrophilicity and predicted secondary structure. The computer program used for the latter was kindly provided by Elias Eliopoulos of the Department of Biophysics, University of Leeds, U.K. and employed a consensus program based on eight of the best known secondary structure prediction programs. Synthesis was conducted with a Beckman 990 peptide synthesizer using the t-Boc solid phase density as previously described (Merrifield et al., 1982) . Following cleavage from methylbenzylhydrylamine resin by the low/high HF procedure (Stewart & Young, 1984) , peptides were desalted in a Sephadex G10 column in acetic acid and lyophilized prior to use. Peptides generated from this resin have C termini in the amido form (Table 1) .
Inoculation of hamsters and passive transfer of MAbs. Peptides were emulsified in an equal volume of Freund's complete adjuvant (FCA) and inoculated subcutaneously into hamsters (500 Ixg/animal). Further peptide immunizations followed 14 and 34 days later using peptides emulsified in Freund's incomplete adjuvant (FIA). Hamsters were bled on days 0, 14, 20, 34 and 44 and challenged 64 days after the first immunization. Tissues were titrated for the presence of virus at 48 h as described previously (Stokes et al., 1989) . The absence of virus was indicative of protection.
For the initial glycoprotein immunization, one group of five hamsters (group 1) received intraperitoneally 1 to 3 Ixg of a purified preparation of EHV-1 gpl3 which had been emulsified in an equal volume of FCA. Further inoculations of 1 to 3 l-tg of glycoprotein were given in FIA on days 19, 33, 53, 90 and 129. Hamsters were challenged with virus 14 days after the final immunization. A second group of eight hamsters (group 3) was inoculated on days 0, 15, and 35 with 1 to 3 ~tg of gpl3 and challenged 14 days later. Two groups of five and eight hamsters served as control animals (groups 2 and 4). Tissues were titrated for the presence of virus 48 h post-challenge as described previously.
Passive transfer studies were carried out as described by Stokes et al. (1989) . Briefly, hamsters received MAb via the heart (0.2 ml), followed by intraperitoneal challenge 1 h later with 2 x 105.3 TCID5o of virus. Tissues were titrated for the presence of virus 48 h later.
Antibody assay systems. For virus neutralization assays, MAbs or
heat-inactivated (56 °C for 1 h) serum samples were serially diluted in Eagle's medium supplemented with 2~ heat-inactivated foetal calf serum (Gibco). Samples were then incubated in the presence or absence of low toxicity guinea-pig complement (10~) (Vector Laboratories) and 100 TCID50 units of virus for 1 h at 37 °C. Virus plus antibody was then added to confluent monolayers of equine foetal kidney (EFK) cells which were examined for cytopathology after 5 days. 
* The sequence of peptide 14/89 was aligned with amino acids contiguous to residue 37 of EHV-I gpl3. Sequences of peptides 15/89 and 16/89 were aligned with EHV-1 sequences by computer. All EHV-4 peptides incorporate a cysteine residue.
t EHV-4 sequence. :~ EHV-1 sequence.
Assays for complement-mediated antibody lysis were carried out as previously described (Stokes et al., 1989) . Briefly EHV-l-infected EFK cells(1 x 105/ml)whichhadbeenlabelledwithNa2SlCrO4(SaCr)were incubated in the presence of heat-inactivated serum or MAb in the presence of low toxicity guinea-pig complement for 3 h at 37 °C. Of the well contents, 50% was harvested and the percentage specific lysis was calculated using the formula: specific lysis (%) = [(test c.p.m. -control c.p.m.)/(total c.p.m. -control c.p.m.)] × 100. The ELISA system using whole viral antigen was identical to that described previously (Stokes et al., 1989) . The anti-EHV-4 peptide ELISA differed by the coating of the solid phase with peptide at a concentration of 3 lag/ml, all additional steps being done using PBS/Tween 20 containing 3 % bovine serum albumin as a diluent. Antibodies were tested for their ability to compete with MAb P28 for binding to whole viral antigen after coating of 96-well microtitre plates (Nunc) overnight at 4 °C with a purified preparation of EHV-1 strain KyD in carbonate/bicarbonate buffer. The next day the plates were washed and a 1/250 dilution of a biotinylated preparation of MAb P28 (25 p.l) diluted in phosphate-buffered saline containing 0-5 % Tween 20 was incubated at 37 °C in the presence or absence of various dilutions of competitor (25 ~tl). The plates were again washed and a 1/200 dilution (50 p.l) of an avidin-horseradish peroxidase conjugate (Sigma) preparation was added. The plates were then incubated at 37 °C for 1 h, washed and the enzyme substrate HzOz was added. The reaction was terminated with 2 ~i-HzSO 4 and A492 was measured.
Results

Properties of MAbs in vitro
Immunoglobulin isotype analysis of the MAbs used in these studies (Table 2) showed that all antibodies belonged to the IgG2a subclass. Antibodies of this class are able to bind to murine macrophages and mediate antibody-dependent cellular cytotoxicity (ADCC) and will also activate the classical complement cascade (Spiegelberg, 1974) . MAbs bound to EHV-1 antigen when tested in an EHV-l-specific ELISA and all antibodies tested with the exception of MAb 16E4 were positive by Western blot analysis of EHV-1 proteins; the glycoprotein specificity of MAb 16E4 was assessed by dot immunoblotting. Two of the MAbs (P28 and 16E4)
showed virus-neutralizing activity in the presence of low toxicity guinea-pig complement and were able to lyse target cells expressing EHV-1 antigens in the presence of complement, MAb P28 being particularly effective. MAb P17, which was unable to neutralize virus infectivity, was able to lyse EHV-l-infected target cells in the presence of complement to a lesser extent.
Properties of MAbs in vivo
To assess the protective properties of the MAbs listed in Table 2 in vivo, they were passively transferred into hamsters which were challenged 1 h later with EHV-1. The titres of virus recovered from hamster tissues after a further 48 h are given in Table 3 . MAb 14H7 has been shown previously to confer to the hamster protection against intranasal or intraperitoneal virus challenge (Stokes et al., 1989) . Resultant virus titres in the livers of the control group of hamsters ranged from 1 x 103 to 1 x l0 s TCIDs0/g and those in the lungs ranged from ~< 1 x 1015 to 1 x 104TCIDso/g. The transferofMAbsP28 or 16E4 prior to virus challenge resulted in the protection of hamsters. MAb P28 protected three hamsters, showing a significant level of reduction of virus in the liver when compared to the control group (P < 0.01); MAb 16E4 protected one animal (P < 0-02). The remaining hamsters in the two groups had reduced levels of virus in the liver when compared to the control group (between 1 x 102 and 1 x 103.5 TCIDs0/g tissue).
Neither MAb 16H9 nor P17 conferred protection (P > 0.01), the titres of virus in the tissues of these two groups of animals being comparable to the controls.
Target analysis of antibodies using MAb P28 in a competition ELISA
MAb P28, which demonstrated virus-neutralizing activity in the presence of complement (Table 2) , was used in II This MAb has previously been shown to confer protection (Stokes et al., 1989) . ND, Not determined. * The mean value for the amount of virus in the livers of animals in this group is significantly different from the mean of the control group as determined by Student's t-test (P < 0.01).
i" This group was not inoculated.
a competition ELISA following biotinylation. The competitors assessed included the remaining anti-gpl3 MAbs, antipeptide antibodies, EHV-l-immune horse serum and EHV-l-immune hamster serum (Table 4) . Results are represented as the percentage inhibition of binding of MAb P28 at a given dilution of the competitor. Thus, the homologous antibody (P28) resulted in 100~ inhibition of binding of labelled antibody at dilutions of 1/10 and 1/20, and 98~ inhibition at dilutions between 1/40 and 1/160; levels of competition became reduced at a dilution of 1/320. MAb 16E4 showed a similar pattern of inhibition but with lower levels of 77~ and 58~ at dilutions of 1/640 and 1/1280; the remaining MAbs did not show competition. Antigp 13 peptide serum from hamsters did not compete with MAb P28. Serum taken 13 and 22 days p.i. of horses with EHV-1 contained virus-neutralizing antibodies; these sera showed inhibition of binding of MAb P28. A serum sample taken from a hamster 42 days p.i., which contained virus-neutralizing antibodies, also demonstrated competitive activity. The competition observed in this assay is indicative of the recognition of a similar neutralizing epitope on gpl 3.
Antibody response of hamsters to immunization with synthetic peptides derived from EHV-4 sequence data and the result of virus challenge
The amino acid sequences of peptides synthesized using EHV-4 gpl 3 sequence data are listed in Table 1 . Amino acids 145 to 150 have been shown to be the most hydrophilic sequence of six contiguous amino acids present in the EHV-1 gpl3 molecule (Allen & Coogle, 1988 ) and the corresponding EHV-4 sequence, of which three amino acids are identical (165 to 167), is also hydrophilic. Peptide 15/89 contained this sequence; peptide 16/89 contains a sequence of amino acids (407 to 412) which is type-common and corresponds to a major hydrophilic peak on the Hopp and Woods hydropathic plot (Hopp & Woods, 1981) . Thus, peptides 15/89 and 16/89 showed a high level of amino acid sequence identity with gpl3 of EHV-1 (75~ and 81~ respectively); peptide 14/89 had 27~o amino acid identity. Peptides were administered to hamsters as described in Methods.
The serum antibody levels obtained on day 44 p.i. are given in Table 5 . All hamsters responded to the peptide immunizations by the formation of antipeptide antibodies measured by the means of a peptide-specific ELISA. In some instances, antibodies were formed which reacted with a whole virus preparation of EHV-1 or EHV-4. Sera from hamsters 103 and 104, immunized with peptide 15/89, contained antipeptide antibodies as early as 14 days after the first peptide immunization (results not shown). Overall this peptide induced the highest titres of antipeptide antibody in all five animals, with levels of > 6400 reciprocal antibody titre in four of five hamsters on day 44.
Anti-EHV-4 responses were measured by the means of a solid-phase ELISA. The highest levels of antiviral sponses were also seen using EHV-1 antigen. Despite these observations, sera were unable to neutralize virus infectivity in v#ro. These hamsters were, however, not protected from infection (Table 6 ). The challenge of peptide-immunized hamsters with live virus resulted in all animals becoming infected, with titres of virus in the liver ranging from 1 x 102 to 1 x 105 TCID50/g tissue. The mean titre of virus in livers from peptide-immunized hamsters did not differ significantly from that of the control group (P > 0.01).
Virus-neutralizing antibody was absent or, where present, was of variable amount, titres of between < 1/10 and 1/60 being observed in the serum from hamsters in group 1. Antibody titres in the serum of the fifth hamster in group 3 were < 1 / 16, < 1 / 16, < 1 / 16, 1/96 and 1/480 on days 0, 8, 15, 41 and 49, respectively. Complementmediated antibody lysis activity using EHV-l-infected EFK cells as targets was demonstrated in vitro using sera from two of these hamsters (data not shown).
Immunogenicity of a purified preparation of EHV-1 gp l 3
Two trials were carried out on separate occasions to test the efficacy of a purified preparation of gpl3 in protecting hamsters against EHV-1 infection. The immunization strategy is outlined in Methods. The first trial resulted in the protection of three of five animals against EHV-1 challenge. The second trial of gpl3 protected six of eight hamsters (Table 7) . Serum antibody levels at the time of challenge were assessed by means of an EHV-l-specific ELISA and were between 1/50 and 1/1600; levels in the control group were < 1/50.
Discussion
The role of EHV-1 glycoproteins in the induction of antiviral immune responses has been demonstrated at the humoral level, serum from EHV-1 convalescent horses immunoprecipitating the high abundance glycoproteins (Allen & Bryans, 1986) , and, at the cellular level, lymphocytes from EHV-l-primed horses showing in vitro proliferative responses in the presence of such virus components (Bridges et al., 1988) . Whether these responses will mediate recovery from infection or protection against re-infection with EHV-1 has not been clearly established. However, glycoproteins from other herpesviruses will induce such protective responses mediated by both the cellular (Blacklaws et al., 1987; Weir et al., 1989) and humoral (Sullivan & Smith, 1987; Weir et al., 1989) immune responses. The work described here was carried out to address the role of one virus glycoprotein, gpl3.
Two MAbs (16E4 and P28) showed complementdependent neutralization of virus, a property previously recorded for MAb 16E4 by Allen et al. (1988) , who established that this antibody recognizes a conserved epitope present on a high percentage of EHV-1 isolates. These workers also confirmed the existence of 16 distinct gp 13 epitopes present on a range of EHV-1 isolates. In comparison, gpC of HSV-I contains two spatially q distinct antigenic sites encompassing nine epitopes (Wu et al., 1990) , which were defined by means of MAbresistant mutant viruses showing single amino acid substitutions. We have also established that MAbs 16E4 and P28 react with the same or overlapping epitopes on the virus particle, both antibodies being more effective in the neutralization of EHV-1 than EHV-4 isolates (results not shown). The existence of further neutralizing NAbs with properties similar to MAb 16E4 has been documented (Sinclair et al., 1989) .
MAbs 16E4 and P28 mediated complement lysis of EHV-l-infected target cells, an immune effector mechanism previously demonstrated using serum samples from EHV-l-infected horses, horses vaccinated with Pneumabort K (Stokes & Wardley, 1988) and EHV-l-immune hamsters (Stokes et al., 1989) . Our studies confirm that gpl3 acts as a target for antibodies mediating this response.
The passive transfer of gpl 3-specific MAbs conferred protection against EHV-1 challenge, a property demonstrated on several occasions (Stokes et al., 1989; Shimizu et al., 1989; Sinclair et al., 1989) . The exact protective mechanism has yet to be defined as, although unlike the other gpl3 MAbs, NAb 14H7 is unable to neutralize virus infectivity in vitro, it will mediate protection. Protection may therefore be mediated by virus neutralization or by other antibody-mediated immune effector mechanisms such as opsonization or ADCC. In the analogous HSV-1 situation, protection of intracranially challenged DBA mice did not correlate with virusneutralizing activity (Kumel et al., 1985) .
The results of the MAb studies were confirmed by using purified gpl3 as an immunogen in the hamster model. The resultant antibody responses were variable between animals, one hamster displaying particularly high levels of serum virus-neutralizing antibody, although a large percentage of animals were protected, supporting the findings of Guo et al. (1989) who showed that the immunization of animals with a vaccinia virus recombinant expressing the gp 13 gene of EHV-1 resulted in the formation of EHV-l-neutralizing antibodies and protection from lethal challenge. Similarly, when a vaccinia virus recombinant expressing the gC gene (the gene with which gpl3 is genetically collinear) of HSV-1 was used to vaccinate mice, it induced both anti-HSV-1 virus-neutralizing antibodies and a cell-mediated immune response, lymphocytes from vaccinated animals showing proliferation in the presence of HSV-1 antigen. Such immunizations resulted in the protection of animals against infection (Weir et al., 1989) . The protection observed in our studies may also have been mediated by a cell-mediated immune response, although further studies are required to evaluate such a mechanism which may consist of the formation of cytotoxic T cells or the induction of a delayed type hypersensitivity reaction.
The results obtained after peptide immunization demonstrated that although the antibodies formed against the peptides cross-reacted with EHV-1 and EHV-4 virus antigens, they were not virus-neutralizing. Therefore, additional peptides will be synthesized with the aim of predicting a virus-neutralizing epitope for use as a subunit vaccine. An instance where this approach was successful was the use of synthetic peptides to define virus-neutralizing epitopes on glycoprotein D of HSV-1 (Weijer et al., 1988) . A 23 amino acid determinant on this glycoprotein was also shown to be antigenic for proliferating T cells (Heber-Katz et al., 1988) .
This paper provides preliminary data on the suitability of EHV-1 gpl3 as a subunit vaccine and has described the results of experiments carried out to evaluate the types of immune effector mechanism which it induces. Among the more important responses resulting from exposure to this antigen were a virus-neutralizing response and complement-mediated antibody lysis, such responses mediating recovery from infection with EHV-1 in the horse (Stokes & Wardley, 1988) and resulting in the protection of the Syrian hamster as described here. Further studies are necessary to evaluate the crossreactivity of immune responses to gpl3 in the hope of producing a vaccine protective against both types of virus.
